Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02313064 · ClinicalTrials.gov registry record · Phase 1
Oral CXA-10 Study in Healthy Volunteers
A Phase 1 study, sponsored by Complexa.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02313064 is a Phase 1 study that has completed, run by Complexa. The registered enrollment target is 40 participants.
The verdict
NCT02313064, a Phase 1 study, has completed, sponsored by Complexa.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This will be the first-in-human (FIH) study with the oral formulation of CXA-10. The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as single ascending oral doses to healthy volunteers (Part A). The effects of food on the PK of CXA-10 will also be investigated (Part B).
Interventions
- DRUG CXA-10
- DRUG CXA-10 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02313064
The ClinicalTrials.gov registry entry for NCT02313064 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Complexa, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CXA-10 is the first listed.
NCT02313064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02313064 about?
NCT02313064 is a clinical study titled "Oral CXA-10 Study in Healthy Volunteers". This will be the first-in-human (FIH) study with the oral formulation of CXA-10. The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as single ascending oral doses to healthy volunteers (Part A). The effects...
What is the current status of trial NCT02313064?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02313064?
The interventions under investigation include: CXA-10 (DRUG), CXA-10 placebo (DRUG).
Who is sponsoring clinical trial NCT02313064?
This trial is sponsored by Complexa, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.